A Curated Platform of Equity & Options Market Intelligence
Select Page

ZNTL

Search by
TICKER SYMBOL

Zentalis Pharmaceuticals Inc

Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing

17.6

0.68

(4.019%)

Volume:

1,217,336

52 week range:

15.55 - 52.85

Market Cap:

1.046B

Company Description:

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of potentially best-in-class oncology candidates, all internally discovered, which include ZN-c5, an oral selective estrogen receptor degrader (SERD) for ER+/HER2- breast cancer, ZN-c3, a WEE1 inhibitor for advanced solid tumors, ZN-d5, a BCL-2 inhibitor for hematologic malignancies, and ZN-e4, an EGFR inhibitor for non-small cell lung carcinoma (NSCLC). Zentalis has licensed ZN-c5, ZN-c3 and ZN-d5 to its majority-owned joint venture, Zentera Therapeutics, to develop and commercialize these candidates in China. Zentalis has operations in both New York and San Diego.